***Percentage of patients who completed study treatment (safety set): 37.5% with Oxycodone/naloxone PR and 66.2% with Tap PR; 76.53% Percent difference between tapentadol PR and oxycodone/naloxone PR, using oxycodone/naloxone PR as the base (denominator). i.e. Approximately 77% more patients stayed on tapentadol PR compared with oxycodone/naloxone PR (77% more adherence).
1. The Bone & Joint Decade Department of Orthopedics: European Action Towards Better Musculoskeletal Health: A Public Health Strategy to Reduce the Burden of Musculoskeletal Conditions. [cited 2010 September 9]. Available from: http://ec.europa.eu/health/ph_projects/2... .
2. Fishbain DA et al. What is the evidence that neuropathic pain is present in chronic low back pain and soft tissue syndromes? An evidence-based structured review. Pain Med. 2014;15(1):4-15.
3. Baron R et al. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-819.
4. Freynhagen R et al. painDETECT: a new screening questionnaire to identify neuropathic components in patients with back pain. Curr Med Res Opin. 2006;22(10 ):1911-1920.
5. Tzschentke TM et al. Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. Drugs Today (Barc). 2009;45(7):483-496.
6. Baron R et al. Effectiveness of tapentadol prolonged release (PR) versus oxycodone/naloxone PR for severe chronic low back pain with a neuropathic pain component. Poster presented at PAIN Week September 2014, Las Vegas, USA.
7. Altman RD et al. Opioid therapy for osteoarthritis and chronic low back pain. Postgrad Med. 2010;122(6):87-97.
8. Porreca F et al. Nausea and vomiting side effects with opioid analgesics during treatment of chronic pain: mechanisms, implications, and management options. Pain Med. 2009;10(4):654-662.
9. Benyamin R et al. Opioid complications and side effects. Pain Physician. 2008;11(2 suppl):S105-S120.
10. Panchal SJ et al. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden. Int J Clin Pract. 2007;61(7):1181-1187.
11. Kalso E et al. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.
12. Binder A et al. Safety and tolerability of tapentadol prolonged release (PR) versus oxycodone/naloxone PR for severe chronic low back pain with a neuropathic pain component. Poster presented at PAIN Week September 2014, Las Vegas, USA.
13. McCarberg BH et al. The impact of pain on quality of life and the unmet needs of pain management: results from pain sufferers and physicians participating in an Internet survey. Am J Ther. 2008;15(4):312-320.
14. Schwittay A et al. Effects of tapentadol prolonged release (PR) versus oxycodone/naloxone PR on quality of life and function measures in patients with severe chronic low back pain with a neuropathic pain component. Poster presented at PAIN Week September 2014, Las Vegas, USA.
Contact
Jeanette Hübsch, Head of Brand Communication Palexia,
Grünenthal Europe & Australia
Phone: +49-241-569-1487, Fax: +49-241-569-3474
jeanette.huebsch@grunenthal.com
